4-amino-pyrrolo[2,3-d]pyrimidin-6-one derivative and use thereof in medicine
By developing a 4-amino-pyrrolo[2,3-d]pyrimidin-6-one derivative as a new sGC modulator or agonist, we solve the problem of existing drugs in the treatment of cardiovascular diseases, renal diseases and respiratory diseases. The problem of toxic side effects and limited therapeutic effects in systemic diseases has been achieved by effectively stimulating sGC activity and reducing side effects.
WO2025016393A1PCT designated stage expired Publication Date: 2025-01-23HAISCO PHARMACEUTICAL GROUP CO LTD
Patent Information
- Application Number
- PCT/CN2024/105872
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-12
- Filing Date
- 2024-07-17
- Publication Date
- 2025-01-23
Smart Images
Figure CN2024105872_23012025_PF_FP_ABST
Abstract
The present invention relates to a 4-amino-pyrrolo[2,3-d]pyrimidin-6-one derivative, and in particular to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite and pharmaceutically acceptable salt or co-crystal thereof, and an intermediate thereof and a preparation method therefor, and a use thereof in the preparation of a drug for treating diseases related to the activity or expression level of guanylate cyclase (sGC).
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Soluble guanylate cyclase activators
CN103096718A
Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
CN103906752A
Substituted annulated pyrimidines and triazines, and use thereof
CN104812762A
4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
CN108738320A